Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIBP-A16 injection in healthy adults
NCT07106918Phase 1Recruiting
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Aug 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SIBP-A16 in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Shanghai Institute of Biological Products. Primary endpoints: Adverse Events at 361 days, Serious Adverse Events at 361 days and 1 more. Started Aug 2025; status: recruiting.
02
Drugs
SIBP-A16
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07106918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07106918.